<title>Soft-tissue injuries from sports activities and traffic accidents--treatment with low-level laser therapy: a multicenter double-blind placebo-controlled clinical study on 132 patients</title>

A double-blind, controlled clinical study with benzydamine hydrochloride 3% cream was conducted in an Occupational Health Centre on fifty patients with soft tissue injuries (two mild, ten moderate and thirteen severe cases in the placebo group and one mild, thirteen moderate and twelve severe cases in the active group). The trial demonstrated the significant therapeutic superiority of 3% benzydamine cream over inactive placebo in all six qualitative parameters for traumatic inflammatory changes at the end of a six-day assessment and a marked improvement of symptoms even two days after the onset of therapy. In addition, the incidental use of ultrasound therapy together with the standard treatment revealed the value of the active drug as an effective couplant. Neither group suffered any side-effects. Although the size of population studied was small, it was apparent that active treatment with benzydamine was a distinct aid to healing of soft tissue injuries and this should be confirmed with further large-scale clinical trials.

Download Full-text

Faculty Opinions recommendation of A randomized, double-blind, placebo-controlled clinical study to assess safety and clinical activity of OTO-104 given as a single intratympanic injection in patients with unilateral Ménière's disease.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.717954645.793463741 ◽

2012 ◽

Author(s):

Marc Bennett

Keyword(s):

Clinical Study ◽

Meniere’S Disease ◽

Clinical Activity ◽

Ménière’S Disease ◽

Menière's Disease ◽

Double Blind ◽

Double Blind Placebo ◽

Intratympanic Injection ◽

Ménière's Disease ◽

Controlled Clinical Study

Download Full-text

Effects of Vigiis 101-LAB on a healthy population's gut microflora, peristalsis, immunity, and anti-oxidative capacity: A randomized, double-blind, placebo-controlled clinical study

Heliyon ◽

10.1016/j.heliyon.2020.e04979 ◽

2020 ◽

Vol 6 (9) ◽

pp. e04979 ◽

Cited By ~ 1

Author(s):

Chien-Li Chen ◽

Jyh-Ming Liou ◽

Tsong-Ming Lu ◽

Yi-Hsien Lin ◽

Chin-Kun Wang ◽

...

Keyword(s):

Clinical Study ◽

Oxidative Capacity ◽

Gut Microflora ◽

Double Blind ◽

Double Blind Placebo ◽

Controlled Clinical Study

Download Full-text

Doppelblinde, randomisierte, placebokontrollierte Low-Level-Laser Therapiestudie bei Patienten mit primärem Raynaudphänomen

VASA ◽

10.1024/0301-1526.31.2.91 ◽

2002 ◽

Vol 31 (2) ◽

pp. 91-94 ◽

Cited By ~ 14

Author(s):

Hirschl ◽

Katzenschlager ◽

Ammer ◽

Melnizky ◽

Rathkolb ◽

...

Keyword(s):

Laser Therapy ◽

Raynaud’S Phenomenon ◽

Raynaud's Phenomenon ◽

Low Level Laser Therapy ◽

Double Blind ◽

Double Blind Placebo ◽

Low Level ◽

Low Level Laser ◽

Level Laser ◽

Primary Raynaud’S Phenomenon

Background: No causal treatment of primary Raynaud’s phenomenon is available due to its unclear aetiology. Low level laser therapy (LLLT) is applied in a multitude of medical conditions often without sufficient evidence of efficacy and established mechanisms. To asses the effect of this therapy in patients with primary Raynaud’s phenomenon a randomised, double blind, placebo controlled cross over study was designed. Patients and methods: Absolute and relative frequency and intensity of vasospastic attacks during three weeks of either LLLT or placebo therapy and results of infrared thermography before onset and at the end of both therapy sequences were evaluated in 15 patients with primary Raynaud’s phenomenon. Results: Frequency of Raynaud’s attacks was not significantly affected by low level laser therapy. Compared to placebo a significantly lower intensity of attacks during laser irradiation was observed, but no transfer effect occurred. Additionally the mean temperature gradient after cold exposure was reduced after laser irradiation, while the number of fingers showing prolonged rewarming was unaffected. Conclusion: Though further studies are necessary to confirm these results we could demonstrate for the first time in a double blind placebo controlled clinical trial that low laser therapy is a potential candidate for an effective therapy of Raynaud`s phenomenon, although effects seem to be of short duration.

Download Full-text